Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
DXCM Transcript
DexCom, Inc. (DXCM) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary and Q&A session reveal positive sentiment. DexCom shows strong financial performance and optimistic guidance with revenue growth projected at 11%-13%. There are promising developments in product launches and expansion of Medicare coverage, particularly for the type 2 non-insulin population. Record new patient starts and international growth further support positive outlook. Although there is some uncertainty about the exact timing of CMS coverage, the overall tone is optimistic. The strategic focus on capital allocation and potential share buybacks also contributes positively to the sentiment.
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-2
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
Positive2-12
DexCom's earnings call indicates positive sentiment with raised revenue guidance, product launches, and international expansion plans. Despite lowered gross profit margin guidance, the company plans to offset this through operating expense leverage. The Q&A section reveals strong engagement in the basal segment, positive early results for the G7 product, and expanding coverage for type 2 diabetes users. While some uncertainties remain, such as CMS coverage timelines, the overall outlook with new product launches and international expansion is optimistic, suggesting a positive stock price reaction.
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
DXCM Slides
DXCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
